{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T20:21:48Z","timestamp":1795119708237,"version":"4.10.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":147,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cancer Research, UK","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}]},{"name":"Cancer Research, UK","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}]},{"name":"Cancer Research, UK","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}]},{"name":"Cancer Research, UK","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}]},{"name":"Cancer Research, UK","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}]},{"name":"Cancer Research, UK","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}]},{"name":"Cancer Research, UK","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}]},{"name":"Cancer Research, UK","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}]},{"name":"Cancer Research, UK","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["14036"],"award-info":[{"award-number":["14036"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["14036"],"award-info":[{"award-number":["14036"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["14036"],"award-info":[{"award-number":["14036"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["14036"],"award-info":[{"award-number":["14036"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["14036"],"award-info":[{"award-number":["14036"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["14036"],"award-info":[{"award-number":["14036"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ductal Carcinoma In Situ (DCIS) is a non-obligate precursor of invasive breast cancer. Due to a lack of reliable prognostic markers, nearly all women with DCIS undergo intensive treatment\u2014often unnecessarily. The LORD trial addresses this by offering active surveillance to women with screen-detected, ER-positive, HER2-negative, grade 1 or 2 DCIS, aiming to reduce overtreatment. To support this, we developed a deep learning pipeline based on foundation models to predict grade, ER, and HER2 status directly from H&amp;E-stained digitized pathology slides. Models were trained and tested on a Dutch multicenter dataset (n\u2009=\u2009887) and externally validated on a UK dataset (n\u2009=\u2009259). On the Dutch data, the models achieved mean AUROCs of 0.90 (ER), 0.84 (HER2), and 0.86 (grade); external validation yielded 0.80, 0.74, and 0.75, respectively. Using these outputs, we stratified patients according to active surveillance criteria, reaching balanced accuracies of 0.81 (Dutch) and 0.64 (UK), with corresponding NPVs of 0.86 and 0.76. Our models generalize across cohorts and reliably predict key biomarkers, supporting the identification of DCIS patients eligible for less aggressive management.<\/jats:p>","DOI":"10.1038\/s41523-026-00957-6","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:26:30Z","timestamp":1778084790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring"],"prefix":"10.1038","volume":"12","author":[{"given":"S.","family":"Doyle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Oerlemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Brunekreef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Bouybayoune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. J.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. E.","family":"Pinder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Grand Challenge PRECISION Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelle","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Nik-Zainal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elinor J.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Futreal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Navin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Shelley","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos","family":"Jonkers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacco","family":"van Rheenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariba","family":"Behbod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther H.","family":"Lips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjanka","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lodewyk F. A.","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Rea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Proteeti","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary","family":"Stobart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Collyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Verschuur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marja","family":"van Oirsouw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. I.","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Teuwen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. H.","family":"Lips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"957_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.breast.2022.01.001","volume":"61","author":"AJ Maxwell","year":"2022","unstructured":"Maxwell, A. J. et al. Unresected screen-detected ductal carcinoma in situ: outcomes of 311 women in the Forget-Me-Not 2 study. Breast Edinb. Scotl. 61, 145\u2013155 (2022).","journal-title":"Breast Edinb. Scotl."},{"key":"957_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-024-07473-w","volume":"208","author":"Q Chen","year":"2024","unstructured":"Chen, Q. et al. Outcomes from low-risk ductal carcinoma in situ: a systematic review and meta-analysis. Breast Cancer Res. Treat. 208, 237\u2013251 (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"957_CR3","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/jnci\/djy220","volume":"111","author":"MD Ryser","year":"2019","unstructured":"Ryser, M. D. et al. Cancer outcomes in DCIS patients without locoregional treatment. J. Natl. Cancer Inst. 111, 952\u2013960 (2019).","journal-title":"J. Natl. Cancer Inst."},{"key":"957_CR4","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/s41416-021-01496-6","volume":"125","author":"M van Seijen","year":"2021","unstructured":"van Seijen, M. et al. Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast. Br. J. Cancer 125, 1443\u20131449 (2021).","journal-title":"Br. J. Cancer"},{"key":"957_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/cjp2.201","volume":"7","author":"M van Seijen","year":"2021","unstructured":"van Seijen, M. et al. Variability in grading of ductal carcinoma in situ among an international group of pathologists. J. Pathol. Clin. Res. 7, 233\u2013242 (2021).","journal-title":"J. Pathol. Clin. Res."},{"key":"957_CR6","doi-asserted-by":"publisher","first-page":"113276","DOI":"10.1016\/j.ejca.2023.113276","volume":"192","author":"RSJM Schmitz","year":"2023","unstructured":"Schmitz, R. S. J. M. et al. Active surveillance versus treatment in low-risk DCIS: Women\u2019s preferences in the LORD-trial. Eur. J. Cancer 192, 113276 (2023).","journal-title":"Eur. J. Cancer"},{"key":"957_CR7","doi-asserted-by":"crossref","unstructured":"Kanbayashi, C. et al. The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA). J. Clin. Oncol. 37, TPS603 (2019).","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS603"},{"key":"957_CR8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1158\/1055-9965.EPI-18-0976","volume":"28","author":"LL Visser","year":"2019","unstructured":"Visser, L. L. et al. Predictors of an invasive breast cancer recurrence after DCIS: a systematic review and meta-analyses. Cancer Epidemiol. Biomarkers Prev. 28, 835\u2013845 (2019).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"957_CR9","doi-asserted-by":"publisher","first-page":"e076022","DOI":"10.1136\/bmj-2023-076022","volume":"383","author":"RSJM Schmitz","year":"2023","unstructured":"Schmitz, R. S. J. M. et al. Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study. BMJ 383, e076022 (2023).","journal-title":"BMJ"},{"key":"957_CR10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/ajcp\/aqaa077","volume":"154","author":"MR Van Bockstal","year":"2020","unstructured":"Van Bockstal, M. R., Berli\u00e8re, M., Duhoux, F. P. & Galant, C. Interobserver variability in ductal carcinoma in situ of the breast. Am. J. Clin. Pathol. 154, 596\u2013609 (2020).","journal-title":"Am. J. Clin. Pathol."},{"key":"957_CR11","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1186\/bcr2128","volume":"10","author":"RM Tamimi","year":"2008","unstructured":"Tamimi, R. M. et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 10, R67 (2008).","journal-title":"Breast Cancer Res."},{"key":"957_CR12","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41416-019-0436-3","volume":"120","author":"IM Miligy","year":"2019","unstructured":"Miligy, I. M. et al. The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. Br. J. Cancer 120, 1075\u20131082 (2019).","journal-title":"Br. J. Cancer"},{"key":"957_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1479-3","volume":"15","author":"S Borgquist","year":"2015","unstructured":"Borgquist, S. et al. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. BMC Cancer 15, 468 (2015).","journal-title":"BMC Cancer"},{"key":"957_CR14","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1158\/1078-0432.CCR-18-0201","volume":"24","author":"LL Visser","year":"2018","unstructured":"Visser, L. L. et al. Clinicopathological risk factors for an invasive breast cancer recurrence after ductal carcinoma in situ-A nested case-control study. Clin. Cancer Res J. Am. Assoc. Cancer Res. 24, 3593\u20133601 (2018).","journal-title":"Clin. Cancer Res J. Am. Assoc. Cancer Res."},{"key":"957_CR15","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/bjc.2012.41","volume":"106","author":"E Rakovitch","year":"2012","unstructured":"Rakovitch, E. et al. HER2\/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br. J. Cancer 106, 1160\u20131165 (2012).","journal-title":"Br. J. Cancer"},{"key":"957_CR16","doi-asserted-by":"crossref","unstructured":"Gong, D. et al. HER2 overexpression in ductal carcinoma in situ is associated with ipsilateral breast cancer recurrence after conservative surgery. Transl. Cancer Res. Available from: https:\/\/tcr.amegroups.org\/article\/view\/39677 (2020).","DOI":"10.21037\/tcr-20-1481"},{"key":"957_CR17","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s41416-020-1023-3","volume":"123","author":"IM Miligy","year":"2020","unstructured":"Miligy, I. M. et al. The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ. Br. J. Cancer 123, 1513\u20131520 (2020).","journal-title":"Br. J. Cancer"},{"key":"957_CR18","first-page":"e13055","volume":"97","author":"ZB Wan","year":"2018","unstructured":"Wan, Z. B. et al. Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion. Medicines 97, e13055 (2018).","journal-title":"Medicines"},{"key":"957_CR19","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.21873\/anticanres.16591","volume":"43","author":"E Zabrocka","year":"2023","unstructured":"Zabrocka, E. et al. Estrogen receptor-negative ductal carcinoma in situ (DCIS) of the breast \u2013 an institutional review of outcomes. Anticancer Res. 43, 4031\u20134036 (2023).","journal-title":"Anticancer Res"},{"key":"957_CR20","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41374-021-00540-6","volume":"101","author":"SC Wetstein","year":"2021","unstructured":"Wetstein, S. C. et al. Deep learning-based grading of ductal carcinoma in situ in breast histopathology images. Lab Investig. 101, 525\u2013533 (2021).","journal-title":"Lab Investig."},{"key":"957_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19334-3","volume":"11","author":"N Naik","year":"2020","unstructured":"Naik, N. et al. Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stains. Nat. Commun. 11, 5727 (2020).","journal-title":"Nat. Commun."},{"key":"957_CR22","unstructured":"Filiot, A., Jacob, P., Kain, A. M. & Saillard, C. Phikon-v2, a large and public feature extractor for biomarker prediction. Preprint at http:\/\/arxiv.org\/abs\/2409.09173 (2024)."},{"key":"957_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43856-024-00695-5","volume":"4","author":"G Shamai","year":"2024","unstructured":"Shamai, G. et al. Clinical utility of receptor status prediction in breast cancer and misdiagnosis identification using deep learning on hematoxylin and eosin-stained slides. Commun. Med. 4, 1\u201316 (2024).","journal-title":"Commun. Med."},{"key":"957_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41379-021-00911-w","volume":"35","author":"S Farahmand","year":"2022","unstructured":"Farahmand, S. et al. Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer. Mod. Pathol. 35, 44\u201351 (2022).","journal-title":"Mod. Pathol."},{"key":"957_CR25","doi-asserted-by":"crossref","unstructured":"Filiot, A. et al. Scaling self-supervised learning for histopathology with masked image modeling. Pathology 2023 Jul [cited 2023 Oct 22]. Available from: http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.07.21.23292757.","DOI":"10.1101\/2023.07.21.23292757"},{"key":"957_CR26","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41591-024-02857-3","volume":"30","author":"RJ Chen","year":"2024","unstructured":"Chen, R. J. et al. Towards a general-purpose foundation model for computational pathology. Nat. Med. 30, 850\u2013862 (2024).","journal-title":"Nat. Med."},{"key":"957_CR27","doi-asserted-by":"publisher","first-page":"102559","DOI":"10.1016\/j.media.2022.102559","volume":"81","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Transformer-based unsupervised contrastive learning for histopathological image classification. Med Image Anal. 81, 102559 (2022).","journal-title":"Med Image Anal."},{"key":"957_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41586-024-07441-w","volume":"630","author":"H Xu","year":"2024","unstructured":"Xu, H. et al. A whole-slide foundation model for digital pathology from real-world data. Nature 630, 181\u2013188 (2024).","journal-title":"Nature"},{"key":"957_CR29","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1038\/s41591-024-03141-0","volume":"30","author":"E Vorontsov","year":"2024","unstructured":"Vorontsov, E. et al. A foundation model for clinical-grade computational pathology and rare cancers detection. Nat. Med. 30, 2924\u20132935 (2024).","journal-title":"Nat. Med."},{"key":"957_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01863-0","volume":"26","author":"R Valieris","year":"2024","unstructured":"Valieris, R. et al. Weakly-supervised deep learning models enable HER2-low prediction from H&E stained slides. Breast Cancer Res. 26, 124 (2024).","journal-title":"Breast Cancer Res."},{"key":"957_CR31","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/his.15144","volume":"84","author":"CY Huang","year":"2024","unstructured":"Huang, C. Y. et al. Deep-learning model to improve histological grading and predict upstaging of atypical ductal hyperplasia \/ ductal carcinoma in situ on breast biopsy. Histopathology 84, 983\u20131002 (2024).","journal-title":"Histopathology"},{"key":"957_CR32","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1097\/PAS.0000000000001306","volume":"43","author":"LL Visser","year":"2019","unstructured":"Visser, L. L. et al. Discordant marker expression between invasive breast carcinoma and corresponding synchronous and preceding DCIS. Am. J. Surg. Pathol. 43, 1574 (2019).","journal-title":"Am. J. Surg. Pathol."},{"key":"957_CR33","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ccell.2023.04.002","volume":"41","author":"SJ Hutten","year":"2023","unstructured":"Hutten, S. J. et al. A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression. Cancer Cell 41, 986\u20131002.e9 (2023).","journal-title":"Cancer Cell"},{"key":"957_CR34","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1097\/01.MP.0000038462.62634.B1","volume":"15","author":"EK Latta","year":"2002","unstructured":"Latta, E. K., Tjan, S., Parkes, R. K. & O\u2019Malley, F. P. The role of HER2\/neu overexpression\/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod. Pathol. 15, 1318\u20131325 (2002).","journal-title":"Mod. Pathol."},{"key":"957_CR35","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/sj.bjc.6605799","volume":"103","author":"CA Purdie","year":"2010","unstructured":"Purdie, C. A. et al. Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. Br. J. Cancer 103, 475\u2013481 (2010).","journal-title":"Br. J. Cancer"},{"key":"957_CR36","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/cam4.715","volume":"5","author":"M Morita","year":"2016","unstructured":"Morita, M. et al. CD8+ tumor-infiltrating lymphocytes contribute to spontaneous \u201chealing\u201d in HER2-positive ductal carcinoma in situ. Cancer Med. 5, 1607\u20131618 (2016).","journal-title":"Cancer Med."},{"key":"957_CR37","unstructured":"Ej, G. et al. Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study. Breast Cancer Res. Treat. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32734520\/."},{"key":"957_CR38","doi-asserted-by":"publisher","first-page":"e061585","DOI":"10.1136\/bmjopen-2022-061585","volume":"12","author":"K Clements","year":"2022","unstructured":"Clements, K. et al. Cohort profile of the Sloane Project: methodology for a prospective UK cohort study of >15 000 women with screen-detected non-invasive breast neoplasia. BMJ Open 12, e061585 (2022).","journal-title":"BMJ Open"},{"key":"957_CR39","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa, F. et al. Scikit-learn: machine learning in Python. J. Mach. Learn Res. 12, 2825\u20132830 (2011).","journal-title":"J. Mach. Learn Res."},{"key":"957_CR40","unstructured":"Ilse, M., Tomczak, J. M. & Welling, M. Attention-based deep multiple instance learning. Proc. 35th International Conference on Machine Learning. pp. 2127\u20132136 (PMLR, 2018)."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00957-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00957-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00957-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T20:02:52Z","timestamp":1795118572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00957-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["957"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-00957-6","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article, the affiliations of the consortium authors were incorrectly listed under the main authors' affiliations. This has now been corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.T. declares being a share owner of Glass Medical AI BV; consulting for ScreenPoint Medical (all active). J.T. received support to attend II-ON BMS conference. J.T. is also a member of the Dutch Cancer Foundation KWF \u2013 Smart Measurement committee, as well as Dutch organization for scientific research\u2014Veni Committee. J.T. is Associate Editor of NPJ Breast Cancer. J.T. was not involved in the journal\u2019s review of, or decisions related to, this manuscript. The other authors do not have a competing interest. The consortium was funded by Cancer Grand Challenges, an initiative from Cancer Research UK and the National Cancer Institute, under project Cancer Grand Challenge PRECISION (C38317\/A24043).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"124"}}